Date Published 
October 2014 

Page Count 
94

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR Bundle

Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Table of Contents

Executive Summary

CHAPTER 1: Age-Related Macular Degeneration 

Wet AMD 

Dry AMD 

CHAPTER 2: Therapeutic Efficacy 

Anti-VEGF therapies 

  • Pegaptanib
  • Bevacizumab
  • Ranibizumab
  • VEGF Trap-EYE

CHAPTER 3: Oraya Therapeutics 

Radiotherapy platform 

  • Automatic Positioning System (APS)
  • I-Guide
  • System software

Radiation dosing 

Potential complications and risk factors 

Competitive advantage 

Challenges and areas of improvement 

Future expectations 

Interview with Jim Taylor 

  • Radiation therapy
  • Competitive advantage
  • Challenges encountered
  • Areas of improvement
  • Future expectations

CHAPTER 4: VisionCare Ophthalmic Technologies 

Company background 

Telescope technology 

Complications and challenges 

Interview with Reena Mishra 

  • Company background
  • Telescope technology
  • Competitive advantage
  • Complications and challenges

CHAPTER 5: Omeros 

Company background 

PharmacoSurgery platform 

Pipeline 

Competitive advantage 

Challenges encountered 

Validation 

Future expectations 

Interview with Greg Demopulos 

  • Company background
  • PharmacoSurgery platform
  • OMS302
  • Competitive advantage
  • Challenges encountered
  • Validation procedure
  • Future expectations 

CHAPTER 6: Kala Pharmaceuticals 

Company background 

Mucosal penetrating products (MPP) 

Competitive advantage 

Future endeavors 

Interview with Kim Brazzell 

  • Company background
  • Mucosal penetrating products (MPP)
  • Challenges encountered
  • Competitive advantage
  • Future endeavor 

CHAPTER 7: Platforms and Products 

CHAPTER 8: Survey of Ocular Industry 

Areas of development 

Promising targets and therapies 

Challenges encountered 

CHAPTER 9: Clinical Trials and Pipeline Data

References